ATE506967T1 - Arzneimittel zur präventiven oder therapeutische behandlung von lebererkrankungen - Google Patents
Arzneimittel zur präventiven oder therapeutische behandlung von lebererkrankungenInfo
- Publication number
- ATE506967T1 ATE506967T1 AT00921077T AT00921077T ATE506967T1 AT E506967 T1 ATE506967 T1 AT E506967T1 AT 00921077 T AT00921077 T AT 00921077T AT 00921077 T AT00921077 T AT 00921077T AT E506967 T1 ATE506967 T1 AT E506967T1
- Authority
- AT
- Austria
- Prior art keywords
- hepatic
- liver diseases
- preventive
- therapeutic treatment
- medicinal products
- Prior art date
Links
- 208000019423 liver disease Diseases 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 229940126601 medicinal product Drugs 0.000 title 1
- 230000003449 preventive effect Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 230000004913 activation Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 210000004024 hepatic stellate cell Anatomy 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 102000000568 rho-Associated Kinases Human genes 0.000 abstract 2
- 108010041788 rho-Associated Kinases Proteins 0.000 abstract 2
- IYOZTVGMEWJPKR-YWRZDDHQSA-N C1C[C@@H](C(N)C)CC[C@@H]1C(=O)NC1=CC=NC=C1 Chemical compound C1C[C@@H](C(N)C)CC[C@@H]1C(=O)NC1=CC=NC=C1 IYOZTVGMEWJPKR-YWRZDDHQSA-N 0.000 abstract 1
- 206010073069 Hepatic cancer Diseases 0.000 abstract 1
- 206010019668 Hepatic fibrosis Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 210000005228 liver tissue Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12062499 | 1999-04-27 | ||
| PCT/JP2000/002797 WO2000064478A1 (fr) | 1999-04-27 | 2000-04-27 | Medicaments destines a soigner et a prevenir les maladies du foie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE506967T1 true ATE506967T1 (de) | 2011-05-15 |
Family
ID=14790843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00921077T ATE506967T1 (de) | 1999-04-27 | 2000-04-27 | Arzneimittel zur präventiven oder therapeutische behandlung von lebererkrankungen |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6794398B1 (de) |
| EP (1) | EP1177796B1 (de) |
| JP (1) | JP4509395B2 (de) |
| KR (1) | KR100812972B1 (de) |
| CN (1) | CN100438910C (de) |
| AT (1) | ATE506967T1 (de) |
| AU (1) | AU4144400A (de) |
| CA (1) | CA2369560C (de) |
| DE (1) | DE60045890D1 (de) |
| ES (1) | ES2365692T3 (de) |
| WO (1) | WO2000064478A1 (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2413313C (en) * | 2000-06-23 | 2011-06-14 | Mitsubishi Pharma Corporation | Antitumor effect potentiators |
| BR0114020A (pt) | 2000-09-20 | 2003-07-22 | Merck Patent Gmbh | 4-amino-quinazolinas |
| JP4851003B2 (ja) * | 2000-12-21 | 2012-01-11 | 田辺三菱製薬株式会社 | 肝臓障害に基づく疾患の予防・治療剤 |
| US7442686B2 (en) | 2001-04-12 | 2008-10-28 | Bioaxone Therapeutique Inc. | Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions |
| US20060134140A1 (en) * | 2001-04-12 | 2006-06-22 | Dana Lasko | Compositions and methods for treating tumor spreading |
| US7829566B2 (en) | 2001-09-17 | 2010-11-09 | Werner Mederski | 4-amino-quinazolines |
| AU2003202263A1 (en) | 2002-01-10 | 2003-07-30 | Bayer Healthcare Ag | Roh-kinase inhibitors |
| CA2473910C (en) | 2002-01-23 | 2011-03-15 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives as rho-kinase inhibitors |
| US6924290B2 (en) | 2002-01-23 | 2005-08-02 | Bayer Pharmaceuticals Corporation | Rho-kinase inhibitors |
| US7645878B2 (en) | 2002-03-22 | 2010-01-12 | Bayer Healthcare Llc | Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof |
| PE20050206A1 (es) * | 2003-05-26 | 2005-03-26 | Schering Ag | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa |
| WO2004108142A2 (en) * | 2003-06-06 | 2004-12-16 | The University Of Manchester | Inhibitors of tip-1 for treatment tissue damage |
| JP2009221164A (ja) | 2008-03-17 | 2009-10-01 | Nitto Denko Corp | 肺線維症処置剤 |
| EP1842557B1 (de) | 2004-12-22 | 2013-10-23 | Nitto Denko Corporation | Arzneimittelträger und arzneimittelträgerkit zur hemmung von fibrose |
| ATE519488T1 (de) * | 2004-12-27 | 2011-08-15 | Novartis Ag | Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten |
| WO2007076360A1 (en) * | 2005-12-22 | 2007-07-05 | Alcon Research, Ltd. | (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions |
| EP1934181A2 (de) * | 2005-10-13 | 2008-06-25 | Devgen NV | Kinaseinhibitoren |
| US7867999B1 (en) | 2005-12-22 | 2011-01-11 | Alcon Research, Ltd. | Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions |
| CA2665415A1 (en) * | 2006-10-12 | 2008-04-17 | Novartis Ag | Use of modified cyclosporins |
| AR064420A1 (es) * | 2006-12-21 | 2009-04-01 | Alcon Mfg Ltd | Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop). |
| US8273900B2 (en) | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
| WO2011021221A2 (en) | 2009-08-17 | 2011-02-24 | Reliance Life Sciences Pvt. Ltd. | Compositions for spinal cord injury |
| JP5950428B2 (ja) | 2010-08-05 | 2016-07-13 | 日東電工株式会社 | 線維化組織から正常組織を再生するための組成物 |
| JP6340162B2 (ja) | 2012-12-20 | 2018-06-06 | 日東電工株式会社 | アポトーシス誘導剤 |
| KR101660815B1 (ko) | 2013-06-13 | 2016-09-29 | 한국생명공학연구원 | 테트라싸이클린 유도체, 이의 약학적으로 허용가능한 염 또는 이의 입체이성질체를 유효성분으로 함유하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물 |
| FR3017868A1 (fr) | 2014-02-21 | 2015-08-28 | Servier Lab | Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP3127915B1 (de) | 2014-04-02 | 2020-08-26 | Nitto Denko Corporation | Von rbp-abstammendes zielmolekül und verwendung davon |
| CN106133024B (zh) | 2014-04-07 | 2019-07-05 | 日东电工株式会社 | 用于疏水性药物递送的新颖的基于聚合物的助水溶物 |
| CN110177771B (zh) * | 2016-09-06 | 2022-12-13 | 代谢科技有限公司 | 用于治疗、预防或改善非酒精性脂肪肝病(NAFLD)、NASH、ALD或肝相关病状的γ-酮醛清除剂的组合物和使用方法 |
| WO2018062134A1 (en) * | 2016-09-27 | 2018-04-05 | Mitsubishi Tanabe Pharma Corporation | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease |
| AU2019361120A1 (en) * | 2018-10-19 | 2021-05-13 | The General Hospital Corporation | Compositions and methods for treatment of liver disease |
| WO2021138331A2 (en) * | 2019-12-30 | 2021-07-08 | Memorial Sloan Kettering Cancer Center | Small molecule inhibitors of ulk1 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57200366A (en) | 1981-06-01 | 1982-12-08 | Asahi Chem Ind Co Ltd | Isoquinoline compound |
| JPS61227581A (ja) | 1985-04-02 | 1986-10-09 | Asahi Chem Ind Co Ltd | 血管拡張剤 |
| JPH0680054B2 (ja) | 1985-06-19 | 1994-10-12 | 吉富製薬株式会社 | ピペリジン誘導体 |
| JPS63185921A (ja) | 1987-01-28 | 1988-08-01 | Takeda Chem Ind Ltd | 肝疾患治療剤 |
| JP2770497B2 (ja) | 1988-11-24 | 1998-07-02 | 吉富製薬株式会社 | トランス―４―アミノ（アルキル）―１―ピリジルカルバモイルシクロヘキサン化合物およびその医薬用途 |
| WO1990005723A1 (en) * | 1988-11-24 | 1990-05-31 | Yoshitomi Pharmaceutical Industries, Ltd. | Trans-4-amino(alkyl)-1-pyridylcarbamoyl-cyclohexane compounds and their medicinal use |
| JP2720348B2 (ja) | 1989-03-30 | 1998-03-04 | 旭化成工業株式会社 | 脳細胞機能障害改善剤 |
| JP3408546B2 (ja) | 1991-02-19 | 2003-05-19 | 旭化成株式会社 | 抗喘息剤 |
| JP2864489B2 (ja) | 1991-02-27 | 1999-03-03 | 吉富製薬株式会社 | 喘息治療剤 |
| JP3275389B2 (ja) | 1991-09-06 | 2002-04-15 | 三菱ウェルファーマ株式会社 | ４−アミノ（アルキル）シクロヘキサン−１−カルボン酸アミド化合物 |
| JPH0597834A (ja) | 1991-10-11 | 1993-04-20 | Morishita Roussel Kk | ２，３，６−トリメチル−５−（テトラヒドロフ ラン−２−イル）ベンゾキノン |
| JP3265695B2 (ja) | 1992-05-12 | 2002-03-11 | 三菱ウェルファーマ株式会社 | ４−置換アミノ（アルキル）シクロヘキサン−１−カルボン酸アミド化合物 |
| JP2893029B2 (ja) | 1992-08-10 | 1999-05-17 | 旭化成工業株式会社 | 心臓保護剤 |
| JPH0680569A (ja) | 1992-09-03 | 1994-03-22 | Asahi Chem Ind Co Ltd | 血小板凝集阻害剤 |
| JP3464012B2 (ja) | 1993-04-05 | 2003-11-05 | 旭化成株式会社 | 精神症候治療剤 |
| JPH0741424A (ja) | 1993-07-28 | 1995-02-10 | Asahi Chem Ind Co Ltd | 抗炎症剤 |
| JPH07277979A (ja) | 1994-04-12 | 1995-10-24 | Asahi Chem Ind Co Ltd | 過粘性症候群治療または予防剤 |
| EP1195372A1 (de) * | 1994-04-18 | 2002-04-10 | Mitsubishi Pharma Corporation | N-Heterozyklisch substitutierte Benzamid Deriviate mit antihypertensiver Wirkung |
| JPH0867637A (ja) | 1994-08-31 | 1996-03-12 | Ajinomoto Co Inc | 肝疾患予防治療薬 |
| US5906819A (en) | 1995-11-20 | 1999-05-25 | Kirin Beer Kabushiki Kaisha | Rho target protein Rho-kinase |
| JP3421217B2 (ja) | 1995-11-20 | 2003-06-30 | 麒麟麦酒株式会社 | Ｒｈｏ標的タンパク質Ｒｈｏキナーゼ |
| US6271224B1 (en) | 1995-12-21 | 2001-08-07 | Alcon Laboratories, Inc. | Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia |
| PT885888E (pt) | 1996-02-02 | 2003-12-31 | Western Therapeutics Inst D | Derivados e farmacos de isoquinolina |
| JPH09227381A (ja) | 1996-02-29 | 1997-09-02 | Asahi Chem Ind Co Ltd | 脳血栓における運動麻痺の改善剤 |
| JPH1045598A (ja) | 1996-04-10 | 1998-02-17 | Asahi Chem Ind Co Ltd | ウイルス感染症予防治療剤 |
| JPH10201480A (ja) | 1996-07-24 | 1998-08-04 | Kirin Brewery Co Ltd | ヒト由来のＲｈｏ標的タンパク質Ｒｈｏキナーゼおよびその遺伝子 |
| JPH1087491A (ja) | 1996-07-26 | 1998-04-07 | Asahi Chem Ind Co Ltd | 転写調節因子阻害剤 |
| NZ334613A (en) * | 1996-08-12 | 2002-02-01 | Welfide Corp | Pharmaceutical agents comprising Rho kinase inhibitor |
| EP0827742A1 (de) | 1996-09-04 | 1998-03-11 | Vrije Universiteit Brussel | Verwendung von Histondeacetylasehemmern zur Behandlung von Fibrose oder Zirrhose |
-
2000
- 2000-04-27 AU AU41444/00A patent/AU4144400A/en not_active Abandoned
- 2000-04-27 DE DE60045890T patent/DE60045890D1/de not_active Expired - Lifetime
- 2000-04-27 EP EP00921077A patent/EP1177796B1/de not_active Expired - Lifetime
- 2000-04-27 AT AT00921077T patent/ATE506967T1/de not_active IP Right Cessation
- 2000-04-27 CA CA2369560A patent/CA2369560C/en not_active Expired - Fee Related
- 2000-04-27 WO PCT/JP2000/002797 patent/WO2000064478A1/ja active Search and Examination
- 2000-04-27 CN CNB008096171A patent/CN100438910C/zh not_active Expired - Fee Related
- 2000-04-27 JP JP2000613468A patent/JP4509395B2/ja not_active Expired - Fee Related
- 2000-04-27 US US09/959,441 patent/US6794398B1/en not_active Expired - Lifetime
- 2000-04-27 ES ES00921077T patent/ES2365692T3/es not_active Expired - Lifetime
- 2000-04-27 KR KR1020017013603A patent/KR100812972B1/ko not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE60045890D1 (de) | 2011-06-09 |
| KR20010110805A (ko) | 2001-12-13 |
| AU4144400A (en) | 2000-11-10 |
| KR100812972B1 (ko) | 2008-03-13 |
| ES2365692T3 (es) | 2011-10-10 |
| CA2369560C (en) | 2011-02-01 |
| EP1177796B1 (de) | 2011-04-27 |
| CA2369560A1 (en) | 2000-11-02 |
| CN1362884A (zh) | 2002-08-07 |
| US6794398B1 (en) | 2004-09-21 |
| WO2000064478A1 (fr) | 2000-11-02 |
| JP4509395B2 (ja) | 2010-07-21 |
| EP1177796A1 (de) | 2002-02-06 |
| CN100438910C (zh) | 2008-12-03 |
| EP1177796A4 (de) | 2003-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE506967T1 (de) | Arzneimittel zur präventiven oder therapeutische behandlung von lebererkrankungen | |
| EP1562897A4 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
| GB0223040D0 (en) | Therapeutic compounds | |
| GB0225475D0 (en) | Therapeutic agents | |
| GB0318447D0 (en) | Therapeutic agents | |
| WO2005004803A3 (en) | Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease | |
| CY1108514T1 (el) | Παραγωγα 1-φαινυλαλκανεκαρβοξυλικου οξεος για τη θεραπεια νευρογενων ασθενειων | |
| MXPA05012323A (es) | Sulfonamidas ciclicas para la inhibicion de gama-secretasa. | |
| GB0225474D0 (en) | Therapeutic agents | |
| WO2005065195A3 (en) | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease | |
| BR9914044A (pt) | ésteres tetrahidropirido | |
| EA200500853A1 (ru) | 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака | |
| NO20045137L (no) | Diketohydrazinderivatforbindelser og legemidler inneholdende forbindelser som aktiv ingrediens | |
| ATE350375T1 (de) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen | |
| PL373903A1 (en) | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease | |
| ATE406893T1 (de) | Pharmazeutische zusammensetzung (kit) enthaltend dihydropyridinonverbindungen und eine verbindung mit immunmodulatorischer (oder antiinflammatorischer) wirkung und ihre verwendung | |
| BRPI0418251B8 (pt) | fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo | |
| TNSN02012A1 (fr) | Derives de pyrimidine nouveaux inhibiteurs de mmp, et compositions les contenant | |
| ATE401314T1 (de) | Benzodiazepin-derivate als gamma-secretase inhibitoren | |
| GEP20053675B (en) | Pyridazinone Aldose Reductase Inhibitors | |
| WO2005032471A3 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
| WO2005051914A8 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
| ATE446285T1 (de) | Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3- thiosubstituierte indol-2-alkinsäuren | |
| DE60115466D1 (de) | Wirkstoffvorläufer von imidazopyridin-derivaten | |
| AR043660A1 (es) | El tratamiento de la enfermedad de alzheimer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |